Patients with localized pancreatic ductal adenocarcinoma (PDAC) are best treated with
surgical resection of the primary tumour and systemic chemotherapy, which provides …

Surgical resection combined with systemic chemotherapy is the cornerstone of treatment for
patients with localized pancreatic cancer. Upfront surgery is considered suboptimal in cases …

The opportunity to detect pancreatic cancer (PC) when potentially curable depends on early
diagnosis and an ability to identify and screen high-risk populations before symptoms arise …

Background In patients undergoing resection for pancreatic cancer, adjuvant modified
fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) improves overall survival …

Despite tremendous gains in the molecular understanding of exocrine pancreatic cancer,
the prognosis for this disease remains very poor, largely because of delayed disease …

Pancreatic cancer is the fourth leading cause of cancer-related death among men and
women in the United States. A major challenge in treatment remains patients' advanced …

Background & Aims Endoscopic ultrasound–guided choledochoduodenostomy with a lumen-
apposing metal stent (EUS-CDS) is a promising modality for management of malignant …

Pancreatic cancer is likely to become the second most frequent cause of cancer-associated
mortality within the next decade. Surgical resection with adjuvant systemic chemotherapy …

PURPOSE Five percent to 9% of pancreatic ductal adenocarcinomas (PDACs) develop in
patients with a germline BRCA1/2 or PALB2 (g BRCA/PALB2+) mutation. Phase IB data from …

Pancreatic cancer is currently one of the most lethal diseases. In recent years, increasing
evidence has shown that reprogrammed metabolism may play a critical role in the …